Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Shimizu, Fumitaka ^a   Tasaki, Ayako ^a   Sano, Yasuteru ^a   Ju, Mihua ^a   Nishihara, Hideaki ^a   Oishi, Mariko ^a   Koga, Michiaki ^a   Kawai, Motoharu ^a   Kanda, Takashi ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN 5; GAMMA INTERFERON; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN G; INTERLEUKIN 17; OCCLUDIN; TIGHT JUNCTION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR ADHESION PROTEIN 1; VASCULOTROPIN; AUTOANTIBODY; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELL; CONTROLLED STUDY; ELECTRIC RESISTANCE; ENZYME BLOOD LEVEL; ENZYME RELEASE; HUMAN; HUMAN CELL; MULTIPLE SCLEROSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TRANSENDOTHELIAL ELECTRICAL RESISTANCE; UPREGULATION; BLOOD; BRAIN; CELL CULTURE; ENDOTHELIUM CELL; METABOLISM; PATHOLOGY; SERUM;

AUTOANTIBODIES; BLOOD-BRAIN BARRIER; BRAIN; CELLS, CULTURED; CLAUDIN-5; ENDOTHELIAL CELLS; HUMANS; IMMUNOGLOBULIN G; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SERUM; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84899793854     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092872     Document Type: Article

References (37)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. N Engl J Med 343, 938-52.
2. Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46, 907-11.
3. Cotton F, Weiner HL, Jolesz FA, Guttmann CR (2003) MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 60, 640-6. (Pubitemid 36246083)
4. Coles AJ, Wing MG, Molyneux P, Paolillo A, Davie CM, et al. (1999) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46, 296-304. (Pubitemid 29416266)
5. Anderson VM, Fox NC, Miller DH (2006) Magnetic resonance imaging measures of brain atrophy in multiple sclerosis. J Magn Reson Imaging 23, 605-18.
6. Zivadinov R, Cox JL (2007) Neuroimaging in multiple sclerosis. Int Rev Neurobiol 79, 449-74.
7. Lassmann H (2007) New concepts on progressive multiple sclerosis. Curr Neurol Neurosci Rep 7, 239-44.
8. Bradl M, Lassmann H (2009) Progressive multiple sclerosis. Semin Immunopathol 31, 455-65.
9. Takeshita Y, Ransohoff RM (2012) Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models. Immunol Rev 248, 228-39.
10. Alvarez JI, Cayrol R, Prat A (2011) Disruption of central nervous system barriers in multiple sclerosis. Biochim Biophys Acta 1812, 252-64.
11. Larochelle C, Alvarez JI, Prat A (2011) How do immune cells overcome the blood-brain barrier in multiple sclerosis? FEBS Lett 585, 3770-80.
12. Kirk J, Plumb J, Mirakhur M, McQuaid S (2003) Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. J Pathol 201, 319-27. (Pubitemid 37258943)
13. Plumb J, McQuaid S, Mirakhur M, Kirk J (2002) Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Brain Pathol 12, 154-69. (Pubitemid 34259917)
14. Leech S, Kirk J, Plumb J, McQuaid S (2007) Persistent endothelial abnormalities and blood-brain barrier leak in primary and secondary progressive multiple sclerosis. Neuropathol Appl Neurobiol 33, 86-98. (Pubitemid 46090313)
15. Leppert D, Ford J, Stabler G, Grygar C, Lienert C, et al. (1998) Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 121, 2327-34. (Pubitemid 28552469)
16. Shimizu F, Kanda T (2013) The Blood-Brain Barrier in Neuroinflammation. In Suzumura A, Ikenaka K, editors. Neuron-Glia Interaction in Neuroinflammation. New York, NY: Springer Science+Business Media New York. pp. 157-79.
17. Murphy G, Knäuper V (1997) Relating matrix metalloproteinase structure to function: why the "hemopexin" domain? Matrix Biol 15, 511-8. (Pubitemid 27190025)
18. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, et al. (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69, 292-302.
19. Sano Y, Shimizu F, Abe M, Maeda T, Kashiwamura Y, et al. (2010) Establishment of a new conditionally immortalized human brain microvascular endothelial cell line retaining an in vivo blood-brain barrier function. J Cell Physiol 225, 519-28.
20. Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, et al. (2003) Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol 161, 653-60. (Pubitemid 36578587)
21. Abbott NJ, Rönnbäck L, Hansson E (2006) Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7, 41-53. (Pubitemid 41828930)
22. Engelhardt B (2010) T cell migration into the central nervous system during health and disease: Different molecular keys allow access to different central nervous system compartments. Clin Exp Neuroimmunol 1, 79-93.
23. Minagar A, Ostanin D, Long AC, Jennings M, Kelley RE, et al. (2003) Serum from patients with multiple sclerosis downregulates occludin and VE-cadherin expression in cultured endothelial cells. Mult Scler 9, 235-8. (Pubitemid 36681887)
24. Hochmeister S, Grundtner R, Bauer J, Engelhardt B, Lyck R, et al. (2006) Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis. J Neuropathol Exp Neurol 65, 855-65. (Pubitemid 44371231)
25. Shimizu F, Sano Y, Takahashi T, Haruki H, Saito K, et al. (2012) Sera from neuromyelitis optica patients disrupt the blood-brain barrier. J Neurol Neurosurg Psychiatry 83, 288-97.
26. Argaw AT, Gurfein BT, Zhang Y, Zameer A, John GR (2009) VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. Proc Natl Acad Sci U S A 106, 1977-82.
27. Argaw AT, Asp L, Zhang J, Navrazhina K, Pham T, et al. (2012) Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. J Clin Invest 122, 2454-68.
28. Su JJ, Osoegawa M, Matsuoka T, Minohara M, Tanaka M, et al. (2006) Upregulation of vascular growth factors in multiple sclerosis: correlation with MRI findings. J Neurol Sci 243, 21-30.
29. Benesová Y, Vasku A, Novotná H, Litzman J, Stourac P, et al. (2009) Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Mult Scler 15, 316-22.
30. Gijbels K, Galargy RE, Steinman L (1994) Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteinases. J Clin Invest 94, 2177-82. (Pubitemid 24379586)
31. Trapp BD, Nave KA (2008) Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 31, 247-69.
32. Zamvil SS, Steinman L (2003) Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis. Neuron 38, 685-8. (Pubitemid 36694776)
33. Zlokovic BV (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57, 178-201.
34. Brosnan CF, Cannella B, Battistini L, Raine CS (1995) Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology 45, S16-21.
35. Engelhardt B, Kappos L (2008) Natalizumab: targeting alpha4-integrins in multiple sclerosis. Neurodegener Dis 5, 16-22. (Pubitemid 350261811)
36. Miller DH, Soon D, Fernando KT, MacManus DG, Barker GJ, et al. (2007) MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 68, 1390-401. (Pubitemid 46659091)
37. Cadavid D, Jurgensen S, Lee S (2013) Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis. PLoS One 8, e53297.